Risks and the UK regulatory position
The UK regulatory position on exosome products in aesthetics and hair, why nothing is licensed for injection, what the topical route means in practice, and the safety considerations that follow.
Published by Northbank Media. Last reviewed 2026-07-31. Information only. This site is not a clinic and gives no medical advice.
No exosome product holds a UK marketing authorisation as an injectable medicine for aesthetic or hair indications. Injection is not a licensed route. The route offered in UK clinics is topical application to skin prepared by microneedling.
Unlicensed does not mean tested and rejected. It means the independent assessment of quality, safety and effectiveness that produces a licence has not been completed for this use. That is a gap in knowledge, and it is also a gap in your protection if something goes wrong.
This is the page most worth reading before you sit down in a consultation. It sets out the UK regulatory position in full, what it means practically, and the safety considerations that follow from it. Regulation moves, so check the current position directly with the MHRA.
The position, stated plainly
No exosome product holds a UK marketing authorisation as an injectable medicine for any aesthetic or hair indication. There is no licensed route for injecting an exosome preparation into skin or scalp for cosmetic purposes. What is offered in UK clinics is topical application to skin that has been prepared, most commonly by microneedling. That route has not been licensed as a medicine either. Treatment being available is not the same as treatment being authorised.
People often hear that and conclude one of two wrong things: either that the treatment must be dangerous, or that the licensing point is a technicality. Neither follows. What follows is narrower and more useful. Nobody independent has examined the manufacturing, the quality control and the clinical data for these products in the way that a licensing process requires, and until somebody has, both the benefits and the harms are matters of assertion rather than record.
The frameworks that apply
There is no single rule covering this. Several regimes touch it, and which one applies depends on what the product is and how it is presented.
| Framework | What it covers | Why it matters here |
|---|---|---|
| Medicines regulation | A product presented as treating or preventing disease, or administered to restore or modify a physiological function, can meet the legal definition of a medicinal product. | A medicinal product requires a marketing authorisation before it can be placed on the UK market. No exosome preparation holds one for aesthetic or hair use. |
| Advanced therapy rules | Products based on human cells or tissue that are substantially manipulated, or used for a purpose other than their original function, can fall within the advanced therapy medicinal product framework. | That framework carries demanding manufacturing and clinical evidence requirements, and is the route a genuine cell derived therapy would have to take. |
| Human tissue rules | Material of human origin brings obligations covering donor consent, traceability and the licensing of establishments that procure, store or process it. | Where a preparation is described as human derived, those obligations are relevant to the supply chain behind it. |
| Cosmetic product rules | A cosmetic is applied to the external surfaces of the body and must be safe under normal and reasonably foreseeable conditions of use. | Application to skin that has just been deliberately breached is difficult to characterise as normal and reasonably foreseeable use of a cosmetic. |
| Medical device rules | The microneedling device itself is a medical device and is regulated as one. | The device being properly regulated tells you nothing about the regulatory status of the substance applied with it, and the two are frequently conflated in marketing. |
| Professional regulation | The practitioner is regulated by their own professional body, and by the standards of the register they belong to. | This is the layer that remains fully intact whatever the product's status, and it is the layer through which most complaints are resolved. |
Two consequences run through all of them. First, a product's classification depends heavily on the claims made for it. A preparation presented as improving the appearance of skin sits in different territory from one presented as treating hair loss, even if the contents are identical. Second, classification determines what evidence had to exist before the product reached the clinic, and for cosmetics and research use items that evidence requirement is far lighter than for a medicine.
Why the route of administration matters
Applied to intact skin, a particle in this size range is very unlikely to reach the dermis in meaningful quantity. The stratum corneum is a barrier evolved for exactly this purpose. A product applied to intact skin is therefore, in practical terms, a cosmetic serum, whatever it contains.
Applied immediately after microneedling, the position changes. The barrier has been deliberately breached, there are open channels into living tissue, and material applied to the surface enters the body. That is the route offered in UK clinics, and it is the route that makes the regulatory question live rather than academic. A product assessed for use on intact skin, if it was assessed at all, has not been assessed for delivery through a breached barrier.
Injection removes any ambiguity. Administering a substance by injection to modify a physiological function is squarely the territory of medicines regulation, and no exosome preparation is authorised for that use in the UK. If a clinic offers injection, that fact should be disclosed to you clearly and before you consent.
What unlicensed actually means for you
Nobody independent has checked the product
Licensing is where a regulator examines manufacturing quality, batch consistency, contamination control, stability and clinical data before a product is used on people. Outside that route none of it has been checked by anyone other than the manufacturer.
You cannot verify what is in the vial
Neither, usually, can the clinic. They can tell you what the supplier states. That is a different thing from verification, and it is worth understanding the difference before consenting.
Adverse effects are not being systematically collected
Rare harms only become visible when large numbers of treatments are recorded and reported centrally. No such collection exists for these products in the UK. The absence of reported problems is therefore not evidence that there are none.
Redress is weaker
You still have recourse against the practitioner through their professional regulator, and consumer law still applies to the transaction. What is missing is the layer that a licensed product carries: a regulator holding a file, a manufacturer bound by the terms of an authorisation, and a defined pharmacovigilance route.
Insurance may be a live question
Cover for treatments outside the licensed route is not universal. It is fair to ask a clinic whether their indemnity covers this specific treatment, and a well run clinic will not be surprised by the question.
The physical risks
These divide into risks that come from the delivery method, which are reasonably well characterised, and risks that come from the preparation, which are not.
| Risk | How common | Source | What it means |
|---|---|---|---|
| Infection | Uncommon | From the delivery step | Any breach of the skin barrier carries a risk. Rising pain, spreading redness or fever after a session needs assessment rather than reassurance. |
| Prolonged redness | Common in a mild form | From the delivery step | Usually settles within days. Redness persisting beyond a fortnight should be reviewed. |
| Post inflammatory hyperpigmentation | More likely in Fitzpatrick IV to VI | From the delivery step | Typically appears two to eight weeks afterwards. Sun avoidance and daily sunscreen are not optional. |
| Bruising and swelling | Common, self limiting | From the delivery step | More pronounced around the eyes and on thin skin. Settles within days. |
| Granuloma or nodule formation | Rare | Reported after various injected and needled substances | Needs specialist assessment. Take the product details with you. |
| Scarring | Rare | From the delivery step | Risk is higher with excessive depth, poor technique or a personal history of keloid scarring. |
| Allergic or hypersensitivity reaction | Not quantified | From the preparation | Cannot be predicted where the composition is not fully disclosed, which is an argument for asking what it contains before treatment. |
| Contamination or batch variability | Not quantified | From the preparation | No independent verification of vial contents is available to you, and in most cases none is available to the clinic either. |
| Unknown long term effects | Not quantified | From the preparation | Follow up in the published work is measured in weeks to months. Long term data does not exist. |
Richly pigmented skin
Post inflammatory hyperpigmentation is the risk that most deserves separate mention. Any procedure creating controlled injury can trigger it, the tendency is greater in Fitzpatrick types IV to VI, and it typically appears two to eight weeks after treatment rather than immediately, which means it is not something you will notice before you have completed a course.
A practitioner experienced in treating richly pigmented skin will raise this before you do, will discuss needling depth and pre treatment, will insist on strict sun avoidance and daily sunscreen afterwards, and will often be willing to treat a small test area first. A practitioner who does not mention it at all has told you something about their experience.
Reporting a problem
- Contact the practitioner who treated you first. They need to know, and they are the person with your records and the product details.
- If you are unwell, contact your GP or NHS 111. Signs of infection, spreading redness, fever or increasing pain after any needling procedure need assessment rather than reassurance.
- A suspected adverse reaction to a medicine, or an incident involving a medical device, can be reported to the MHRA through its reporting scheme. Reporting matters most precisely where systematic data does not exist.
- Concerns about the conduct of a registered professional go to the General Medical Council or the Nursing and Midwifery Council. The Joint Council for Cosmetic Practitioners and Save Face operate complaints routes for those on their registers.
What proper consent looks like here
Consent for a treatment outside the licensed route has to carry more, not less, information than consent for a licensed one. A complete discussion covers what the product is and where it comes from, that it is not licensed as a medicine for this use, what that means, what the evidence does and does not show, what the realistic outcome is, what the alternatives are including doing nothing and including the licensed options where they exist, what the risks are, what the total cost is including maintenance, and what happens if something goes wrong.
If a consultation covers price, package and photographs but not the regulatory position, the consent you have given is incomplete. The twelve questions are designed to fill exactly those gaps, and the evidence page explains why the licensing gap and the evidence gap are the same problem seen from two directions.
Common questions
Is exosome therapy banned in the UK
It is not accurate to describe it as banned, and it is not accurate to describe it as approved either. No exosome product holds a marketing authorisation as a medicine for aesthetic or hair use, which means there is no licensed route for injecting one. Products are supplied to clinics under other classifications and applied topically. Whether a particular product and a particular use fall within medicines regulation depends on the product and how it is presented. Check the current position with the MHRA.
What should I ask a clinic about the product
Four questions. What exactly is the preparation and what is it derived from. Who supplies it and what documentation do you hold. What is it classified as for regulatory purposes. On what basis is it being applied in this way. A practitioner who has engaged with the issue can answer all four without difficulty. Evasion on any of them is itself an answer.
What are the actual physical risks
The delivery step carries the risks of any needling procedure: infection, prolonged redness, bruising, pigment change particularly in richly pigmented skin, granuloma formation and rarely scarring. The preparation carries risks that cannot be quantified, because the products are not standardised and no systematic UK collection of adverse events exists for them. Unquantified is a more accurate word than low.
What do I do if something goes wrong
Contact the practitioner who treated you first, and if you are unwell contact your GP or NHS 111. A suspected adverse reaction to a medicine or an incident involving a medical device can be reported to the MHRA through its reporting scheme. If your concern is about the conduct of a registered professional, the relevant regulator is the GMC or the NMC, and the JCCP operates a complaints route for registrants.
Does the topical route avoid the regulatory issue
Not obviously. A product assessed for application to intact skin is being applied to skin deliberately breached with needles moments earlier, which delivers it into living tissue. That is difficult to describe as normal and reasonably foreseeable use of a cosmetic. The topical route changes the practical delivery question; it does not settle the regulatory one.
This page contains no commercial links of any kind. No clinic, practitioner, product or supplier is named, recommended or linked to, and nobody has paid for, influenced or previewed anything on it. External links go only to UK regulators and professional bodies and carry a nofollow attribute. Published by Northbank Media under our editorial policy.
If you want to speak to someone
We are not a clinic and we give no medical advice. If you would like to, we can pass your details to a registered UK practitioner who will contact you directly. Nothing is booked on your behalf and there is no obligation. Read the regulation page first.
Make an enquiry